HIV protease inhibitors as new treatment options for Kaposi’s sarcoma
- 31 August 2003
- journal article
- research article
- Published by Elsevier in Drug Resistance Updates
- Vol. 6 (4) , 173-181
- https://doi.org/10.1016/s1368-7646(03)00060-8
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Matrix Metalloproteinases (MMPs) Regulate Fibrin-invasive Activity via MT1-MMP–dependent and –independent ProcessesThe Journal of Experimental Medicine, 2002
- Serum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival ProbabilityAIDS Research and Human Retroviruses, 2001
- Biology of Kaposi's sarcomaEuropean Journal Of Cancer, 2001
- Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease InhibitorsJournal of Biological Chemistry, 2000
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort StudyThe Journal of Infectious Diseases, 1996
- Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.Journal of Clinical Investigation, 1994
- Angiogenic potential in vivo by Kaposiʼs sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2AIDS, 1994
- Rational Design of Peptide-Based HIV Proteinase InhibitorsScience, 1990